When looking for the best stocks to buy and watch, focus on those with rising relative price strength.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This proprietary rating measures technical performance by showing how a stock’s price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains typically have an 80 or higher RS Rating at the beginning of a new run.
Is I-Mab Stock A Buy?
I-Mab stock is trying to complete a consolidation with an 85.50 buy point. See if it can clear the breakout price in heavy trade. It’s a later-stage pattern, and investors should be aware that those are less likely to launch sustained new climbs. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips. Also, check out “Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks.”
Earnings growth dropped last quarter from 0% to -79%. But revenue gains moved higher, from -100% to 5,528%.
I-Mab stock earns the No. 51 rank among its peers in the Medical-Biomed/Biotech industry group. Regeneron Pharmaceutical (REGN), Biontech Se Ads (BNTX) and Alkermes (ALKS) are among the top 5 highly rated stocks within the group. For more industry news, check out “Biotech And Pharmaceutical Industry And Stock News.”
YOU MIGHT ALSO LIKE:
Business News Governmental News Finance News